Scientists find a surprising clue to why GLP-1 drugs work so well

The extraordinary effectiveness of drugs such as Ozempic and Wegovy has generally been attributed to something fairly straightforward: They make people less hungry.

A new Yale study suggests the story may be considerably more complicated.

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, appears to recruit a group of brain cells traditionally thought of as the body's hunger neurons to help maintain fat loss.

That was nearly the opposite of what scientists expected.

The neurons, known as agouti-related peptide, or AgRP, neurons, have long been regarded as part of the brain's defense against starvation and weight loss. When the body senses a shortage of calories, they become active and stimulate hunger.

Researchers therefore expected successful weight-loss drugs to suppress them.

Instead, semaglutide appears to activate them.

“This completely changes how we think about the mechanism involved in these medications,” said Mateus d'Ávila, a Yale neuroscience Ph.D. candidate and first author of the study.

The findings, published in the Proceedings of the National Academy of Sciences, could help explain one of the enduring mysteries surrounding GLP-1 drugs: Why do they produce dramatically greater and more sustained weight loss than previous generations of appetite suppressants?

More than an appetite suppressant

Earlier obesity drugs could reduce hunger substantially, yet typically produced considerably less weight loss than today's GLP-1 medications.

That discrepancy led the Yale researchers to suspect semaglutide was doing something besides simply making animals eat less.

They focused on AgRP neurons, which play a central role in controlling hunger and the body's response to calorie deprivation.

Using mice, researchers measured food consumption, body weight, metabolism and energy expenditure during semaglutide treatment.

They then genetically removed or silenced the AgRP neurons.

The result was striking.

Semaglutide could still initiate weight loss, but it could no longer sustain that weight loss when the AgRP neurons were absent, according to the researchers.

Additional laboratory work, including electron microscopy, molecular analysis and measurements of electrical activity in the neurons, indicated that semaglutide was activating the neurons rather than shutting them down.

The researchers believe the neurons may have a dual role.

As the calorie deficit caused by GLP-1 treatment develops, AgRP neurons become more active. While these cells are well known for stimulating hunger, the study suggests they may simultaneously participate in coordinating the body's loss of fat.

In other words, part of the biological system traditionally viewed as fighting weight loss may under some circumstances help maintain it.

What this means if you take a GLP-1

The new Yale study does not mean GLP-1 users need to feel hungry for the drugs to work. Nor does it suggest that patients should change their dose, diet or treatment plan.

The research was conducted in mice and was designed to investigate the brain circuitry behind semaglutide's effects.

What researchers found is that a group of neurons normally associated with hunger — AgRP neurons — may also play an unexpected role in helping the body sustain fat loss during GLP-1 treatment.

For patients, the practical takeaways are simpler:

• Keep taking your medication as prescribed. The study does not change current treatment recommendations.
• Don't try to manipulate hunger. Feeling hungrier or eating less is not something patients should attempt to induce based on these findings.
• Expect the science to keep evolving. Researchers are still learning why GLP-1 drugs produce much greater weight loss than older appetite suppressants.
• Future drugs may improve on today's GLP-1s. Understanding the brain pathways involved could eventually help scientists develop treatments that preserve weight-loss benefits while reducing nausea, gastrointestinal problems or other side effects.

For now, the study is best viewed as an important clue about why GLP-1 drugs work — not a reason for patients to change how they use them.

Why it matters

The discovery could help researchers understand why GLP-1 drugs have succeeded where so many earlier obesity treatments failed.

Semaglutide and other GLP-1 therapies don't merely suppress appetite. They appear to change a much broader network of signals controlling food intake, metabolism and the body's response to losing weight.

Understanding those pathways could eventually help drug developers separate the desirable effects of GLP-1 treatment from some of its drawbacks.

“By identifying a previously unrecognized neural mechanism involved in sustaining weight loss, our work provides new biological insights that could eventually help researchers design therapies that are even more effective or have fewer side effects,” d'Ávila said.

That possibility is increasingly important as researchers look beyond the first generation of GLP-1 drugs toward treatments that combine several hormonal and metabolic pathways.

Don't expect a new treatment tomorrow

There is an important limitation: The Yale experiments were conducted in mice.

Mouse studies are invaluable for investigating individual brain circuits because researchers can genetically remove or manipulate specific neurons — experiments that obviously can't be performed in people.

But results in mice don't always translate into human biology.

The study therefore doesn't change how doctors should prescribe semaglutide or how patients should use it.

Instead, it provides a possible explanation for what is happening deep inside the brain during treatment — and a target for future research.

The finding may also help explain why obesity has proven so difficult to treat.

The body's mechanisms regulating weight aren't simply an accelerator controlling hunger and a brake suppressing it. They are overlapping systems that influence appetite, metabolism, energy expenditure and fat stores simultaneously.

GLP-1 drugs may work unusually well because they tap into several of those systems at once.

And, surprisingly, one of the brain circuits helping them do it may be the very circuit scientists once assumed would try to stop them.